|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2008-3-4
|
|
pubmed:abstractText |
Proteasome inhibition results in cytotoxicity to the leukemia stem cell in vitro. We conducted this phase I study to determine if the proteasome inhibitor bortezomib could be safely added to induction chemotherapy in patients with acute myelogenous leukemia (AML).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:AmreinPhilip CPC,
pubmed-author:AttarEyal CEC,
pubmed-author:BallenKaren KKK,
pubmed-author:D'AmatoFerdinandoF,
pubmed-author:De AngeloDaniel JDJ,
pubmed-author:GalinskyIleneI,
pubmed-author:LevineJamesJ,
pubmed-author:McAfeeSteveS,
pubmed-author:MillerKenneth BKB,
pubmed-author:NeubergDonnaD,
pubmed-author:SchenkeinDavidD,
pubmed-author:SirulnikAndresA,
pubmed-author:StoneRichard MRM,
pubmed-author:SupkoJeffrey GJG,
pubmed-author:TrehuElizabeth GEG,
pubmed-author:WadleighMarthaM,
pubmed-author:ZahriehDavidD
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1446-54
|
|
pubmed:meshHeading |
pubmed-meshheading:18316568-Adolescent,
pubmed-meshheading:18316568-Adult,
pubmed-meshheading:18316568-Aged,
pubmed-meshheading:18316568-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18316568-Boronic Acids,
pubmed-meshheading:18316568-Cohort Studies,
pubmed-meshheading:18316568-Cytarabine,
pubmed-meshheading:18316568-Female,
pubmed-meshheading:18316568-Gene Expression Profiling,
pubmed-meshheading:18316568-Humans,
pubmed-meshheading:18316568-Idarubicin,
pubmed-meshheading:18316568-Leukemia, Myeloid, Acute,
pubmed-meshheading:18316568-Male,
pubmed-meshheading:18316568-Maximum Tolerated Dose,
pubmed-meshheading:18316568-Middle Aged,
pubmed-meshheading:18316568-Neoplasm Recurrence, Local,
pubmed-meshheading:18316568-Oligonucleotide Array Sequence Analysis,
pubmed-meshheading:18316568-Pyrazines,
pubmed-meshheading:18316568-Tissue Distribution,
pubmed-meshheading:18316568-Treatment Outcome,
pubmed-meshheading:18316568-Tumor Markers, Biological
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.
|
|
pubmed:affiliation |
Hematology/Oncology Unit, Massachusetts General Hospital, Boston, MA 02114, USA. eattar@partners.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
